Mumbai, Maharashtra, India, February 2026 – Cipla has appointed Ashay Kautikwar as National Sales Head, entrusting him with the responsibility of driving operational excellence and route-to-market (RTM) innovation across the Cipla Vista portfolio.
In his new role, Ashay will focus on balancing high-volume traditional trade channels with the rapid scale-up of emerging channels including e-commerce, quick commerce, organised retail chains, and omnichannel platforms. His mandate is to ensure that the Cipla Vista portfolio continues to set benchmarks for accessibility, reach, and commercial agility within India’s pharmaceutical landscape.
Ashay brings over five years of progressive leadership experience within Cipla, most recently serving as Head – Marketing & Commercial Excellence, where he strengthened operational effectiveness, governance, productivity, and capability building across the business. Prior to that, as Senior Marketing Head and Marketing Head, he led product portfolio strategy, digital business initiatives, sales force effectiveness (SFE), sales force automation (SFA), and people capability development initiatives.
Earlier in his career, Ashay held key marketing roles at Alembic Pharmaceuticals Limited and Macleods Pharmaceuticals Ltd., further sharpening his expertise in brand strategy and commercial execution. Notably, he also had a previous six-year stint at Cipla as Group Product Manager, Senior Product Manager, and Product Manager, contributing to portfolio growth and brand building across therapeutic segments.
An MBA in Marketing from MITSOM | MIT School of Management, Ashay combines deep pharmaceutical marketing expertise with strong trade channel and digital commerce capabilities.
His appointment reflects Cipla’s continued emphasis on strengthening its commercial engine and enhancing omnichannel presence to ensure broader patient access and sustainable growth.
About Cipla
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients worldwide since 1935. Guided by its purpose of “Caring for Life,” Cipla operates in over 80 countries, offering more than 1,500 products across 50+ dosage forms. The company is recognized for its commitment to accessibility and affordability, including its landmark initiative to provide triple anti-retroviral therapy for HIV/AIDS at less than a dollar a day in Africa. With a strong presence across the healthcare continuum, Cipla continues to advance its aspiration of becoming a global lung leader while delivering high-quality medicines worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
